Last reviewed · How we verify
Treatment with nifedipine
Nifedipine works by inhibiting the L-type calcium channels in smooth muscle cells, leading to vasodilation and a decrease in blood pressure.
Nifedipine works by inhibiting the L-type calcium channels in smooth muscle cells, leading to vasodilation and a decrease in blood pressure. Used for Angina pectoris, Hypertension.
At a glance
| Generic name | Treatment with nifedipine |
|---|---|
| Sponsor | Laboratorios Richmond S.A.C.I.F. |
| Drug class | Calcium channel blocker |
| Target | L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This results in a reduction in peripheral resistance and a subsequent decrease in blood pressure. Nifedipine is a calcium channel blocker, which means it blocks the influx of calcium ions into smooth muscle cells, leading to muscle relaxation and vasodilation.
Approved indications
- Angina pectoris
- Hypertension
Common side effects
- Edema
- Dizziness
- Headache
- Nausea
- Flushing
Key clinical trials
- Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NA)
- PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA. (PHASE3)
- 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks
- Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NA)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Intensive Postpartum Antihypertensive Treatment (PHASE3)
- Preeclampsia Postpartum Antihypertensive Treatment (PHASE3)
- The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment with nifedipine CI brief — competitive landscape report
- Treatment with nifedipine updates RSS · CI watch RSS
- Laboratorios Richmond S.A.C.I.F. portfolio CI